Other Events ·
Silexion Therapeutics Corp received a delisting notice from Nasdaq on August 18, 2026, for failing to maintain the…
SLXNSilexion Therapeutics Corp
Silexion Therapeutics Corp received a delisting notice from Nasdaq on August 18, 2026, for failing to maintain the minimum $2.5 million shareholders' equity requirement under Listing Rule 5550(b)(1). The company reported shareholders’ equity of only $44,000 as of June 30, 2026, and does not meet alternative continued listing standards. Silexion intends to appeal the determination before a Nasdaq Hearings Panel by August 25, 2026. The company is subject to a Mandatory Hearings Panel Monitor following a September 23, 2025 decision, which prevents Nasdaq from granting additional time for compliance during the one-year monitoring period. If the appeal fails, trading in ordinary shares and warrants would be suspended and removed from Nasdaq listing. Silexion Therapeutics Corp operates as a clinical-stage biopharmaceutical company focused on developing novel therapies.